TCRX
Tscan Therapeutics Inc

799
Mkt Cap
$55.53M
Volume
674,593.00
52W High
$4.94
52W Low
$0.91
PE Ratio
-0.87
TCRX Fundamentals
Price
$1.05
Prev Close
$0.9785
Open
$0.9967
50D MA
$1.72
Beta
1.17
Avg. Volume
763,452.00
EPS (Annual)
-$1.14
P/B
0.39
Rev/Employee
$14,515.46
Loading...
Loading...
News
all
press releases
Equities Analysts Issue Forecasts for TCRX FY2025 Earnings
TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities researchers at HC Wainwright raised their FY2025 EPS estimates for TScan Therapeutics in a research note issued on Thursday, November...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Wedbush Reduces Earnings Estimates for TScan Therapeutics
TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at Wedbush dropped their FY2025 EPS estimates for TScan Therapeutics in a research note issued to investors on Wednesday...
MarketBeat·9d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Downgraded by Morgan Stanley to "Equal Weight"
Morgan Stanley cut shares of TScan Therapeutics from an "overweight" rating to an "equal weight" rating in a research note on Friday...
MarketBeat·11d ago
News Placeholder
HC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock Price
HC Wainwright reduced their price objective on shares of TScan Therapeutics from $10.00 to $7.00 and set a "buy" rating for the company in a research note on Thursday...
MarketBeat·12d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of...
MarketBeat·13d ago
News Placeholder
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.00% and -21.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Recommendation of "Moderate Buy" by Analysts
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven analysts that are currently covering the firm, MarketBeat Ratings...
MarketBeat·15d ago
News Placeholder
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +60.80% and +50.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Novavax (NVAX) Reports Q3 Loss, Beats Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of +42.59% and +77.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of +36.00% and +55.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·21d ago

Latest TCRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.